Get the Stockscreener App
37.46
2.57%
-0.99
After Hours:
37.46
Harrow Inc stock is traded at $37.46, with a volume of 516.65K.
It is down -2.57% in the last 24 hours and down -10.96% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$38.45
Open:
$39.162
24h Volume:
516.65K
Relative Volume:
0.64
Market Cap:
$1.40B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-229.11
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
-15.73%
1M Performance:
-10.96%
6M Performance:
-12.84%
1Y Performance:
+3.51%
1-Day Range:
$37.36
$39.93
1-Week Range:
$37.36
$45.36
52-Week Range:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
37.46 | 1.43B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harrow Schedules Aug. 11 Call to Discuss Second-Quarter Results - Stock Titan
Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harrow, Inc. Revenue Breakdown – NASDAQ:HROW - TradingView
Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Harrow Inc (HROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harrow Inc (HROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HROW|Harrow Inc|Price:39.409|Chg%:+0.959 - TradingKey
Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis - TradingKey
HROW|Harrow Inc|Price:41.520|Chg%:-0.360 - TradingKey
BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63 - Moomoo
HROW Reiterated by BTIG -- Price Target Maintained at $63.00 - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: Strong Buy Ratings and 52% Potential Upside Drive Investor Interest - DirectorsTalk Interviews
Harrow Inc (HROW) Shares Fall 4.7% -- What GF Score of 80 Tells Investors - GuruFocus
Samsung Bioepis, Harrow present SB11 biosimilar study results By Investing.com - Investing.com South Africa
Harrow (HROW) Unveils Positive Interim Data on SB11 at Retina Sp - GuruFocus
Samsung Bioepis, Harrow present SB11 biosimilar study results - Investing.com India
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 - The Manila Times
Samsung Bioepis and Harrow Present Interim Data from a - GlobeNewswire
Harrow presents studies on eye care products at medical meeting By Investing.com - Investing.com Nigeria
Harrow Announces ASRS 2026 Presentation of Studies Supporting IHEEZO and BYOOVIZ in Retina Care - Quiver Quantitative
Harrow presents new clinical data supporting IH... - Pluang
Harrow presents studies on eye care products at medical meeting - Investing.com
Nearly 20,000 Injections: IHEEZO Finds No Evidence of Added Endophthalmitis Risk - Stock Titan
Harrow Health stock trades steady as recent earnings and product expansion frame the outlook - AD HOC NEWS
Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 80 Tells Investors - GuruFocus
Harrow Among 3 Prime Growth Stocks With Significant Insider Ownership - simplywall.st
Harrow stock rises on recent results and market value - Ad-hoc-news.de
HROW6348836 Bond Profile — Key Metrics - TradingView
HROW6348836 Bond Coupon Profile — Rate & Payments - TradingView
Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 81 Tells Investors - GuruFocus
Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem (NASDAQ:HROW) - Seeking Alpha
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $59 - Moomoo
Harrow Inc. (HROW) Slips 1% But Holds Key Support Above $40Dividend Growth Stocks - DonanımHaber
Analysts Are Optimistic We'll See A Profit From Harrow, Inc. (NASDAQ:HROW) - 富途牛牛
HROW Q1 2026 Earnings: EPS Misses Estimates Sharply Amid Operational ChallengesQuarterly Earnings - dars.gov.et
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow relaunches biosimilar Byooviz in the US - Eyes On Eyecare
Harrow Announces Commercial Launch of BYOOVIZ® in the United States - Sahm
Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to book forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to earnings forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to sales forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Enterprise value to EBIT forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Enterprise value to revenue forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Harrow Expands Retina Portfolio With US Launch of Byooviz - marketscreener.com
Harrow (HROW) Launches Byooviz, FDA-Approved Biosimilar - GuruFocus
Harrow (HROW) Launches BYOOVIZ Biosimilar in U.S. Market - GuruFocus
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):